See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. The future may be getting brighter in terms of reducing the threat of ...
The Trump administration's funding cuts to PEPFAR and USAID disrupted global HIV treatment and prevention, threatening progress made over decades. Lenacapavir's FDA approval as a long-acting ...
Although new HIV infections and AIDS-related deaths are at their lowest levels in more than 30 years, the current HIV response is extremely fragile. Efforts to end AIDS as a public health threat by ...
A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year. Gilead Sciences, GSK, ViiV Healthcare 1 to 3 years In June 2024, results from a trial ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment ...
Solving HIV vaccination—a puzzle that scientists have been tackling for decades without success—could be like cracking the code to a safe. The key, they now think, may be delivering a series of ...
Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response with just one dose. By combining two immune-boosting adjuvants alum and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results